2018
Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study
Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case−control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAgedAngiotensin Receptor AntagonistsAntihypertensive AgentsBlack or African AmericanBlood PressureCalcium Channel BlockersCase-Control StudiesDiabetes Mellitus, Type 2Electronic Health RecordsFemaleHumansHypertensionLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrevalenceTennesseeWhite PeopleConceptsElectronic health recordsResistant hypertensionBlood pressureChronic kidney disease stage 3Mineralocorticoid receptor antagonist useClinical treatmentDihydropyridine calcium channel blockerAntihypertensive medication classesControlled blood pressureOutpatient blood pressureTotal hypertensive populationAngiotensin receptor blockersTransient ischemic attackDisease stage 3Health recordsMineralocorticoid receptor antagonistsReceptor antagonist useHigh blood pressureIschemic heart diseaseAlpha-2 agonistsBody mass indexCalcium channel blockersAfrican American patientsNumber of patientsType 2 diabetes
2017
Genetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population
Kodaman N, Sobota RS, Asselbergs FW, Oetjens MT, Moore JH, Brown NJ, Aldrich MC, Williams SM. Genetic Effects on the Correlation Structure of CVD Risk Factors Exome-Wide Data From a Ghanaian Population. Global Heart 2017, 12: 133-140. PMID: 28408189, PMCID: PMC5642993, DOI: 10.1016/j.gheart.2017.01.013.Peer-Reviewed Original ResearchConceptsPlasminogen activator inhibitor-1CVD risk factorsRisk factorsCardiovascular disease risk factorsDisease risk factorsHigh blood pressureActivator inhibitor-1Dissolution of thrombusArterial pressureBlood pressureMyocardial infarctionPlasma concentrationsStudy participantsGhanaian populationInhibitor-1Significant heterogeneityHeterogeneity of correlationAfrican AmericansGenetic variantsGenetic association studiesDirect role
2011
CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow
Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. Journal Of Hypertension 2011, 29: 1913-1918. PMID: 21873888, PMCID: PMC3309034, DOI: 10.1097/hjh.0b013e32834aa786.Peer-Reviewed Original ResearchConceptsMean arterial pressureHigh salt intakeRenal blood flowHypertensive individualsBlood pressureSalt intakeC alleleSalt restrictionNormotensive individualsBlood flowSalt-sensitive blood pressureSalt sensitivityLow-salt dietDiagnosis of hypertensionHigh blood pressureSalt-sensitive hypertensionRenal vasodilationPressor responseSalt dietArterial pressureAngiotensin IIAttenuated increaseSodium homeostasisCYP4A11 T8590C polymorphismHypertension
2005
Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia
Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. Journal Of Human Hypertension 2005, 20: 129-136. PMID: 16292348, DOI: 10.1038/sj.jhh.1001948.Peer-Reviewed Original ResearchConceptsHigh sodium dietPrimary hyperaldosteronismModerate hypertensionSodium restrictionHypertensive populationLow serum potassium levelsNormotensive control populationSerum potassium levelsHigh blood pressureSpecific cutoff valuesElevated AERElevated ARRHaemodynamic testingNormotensive populationResistant hypertensionHypertensive subjectsNormotensive subjectsSerum aldosteroneBlood pressureEssential hypertensivesMedication washoutStudy protocolHypokalaemiaCutoff valueControl population